首页» 教师队伍» 导师介绍

导师介绍

李开龙 副研究员

df3df0dde03f4244ba161641d5c55a4c.jpg

李开龙 博士

副研究员,博士生导师

国自然青年基金B类(原国家优青)获得者

Email: kailongli@bjmu.edu.cn

实验室网页:https://www.x-mol.com/groups/kailong_li_lab


1. 个人简介:

李开龙,生物化学与分子生物学系课题组组长,细胞稳态与衰老性重大疾病北京研究中心、蛋白质修饰与细胞功能北京市重点实验室PI,博士生导师。博士毕业于北京协和医学院,于美国西南医学中心完成博士后训练,2021年入职基础医学院,长期从事肿瘤表观调控机制与干预的研究。相关研究成果以通讯/第一作者(含共同)发表于Cancer Discovery (2024,2020), Nucleic Acids Research (2025), Science Advances (2024)及Nature Communications (2020,2018)等期刊。承担国自然青年科学基金项目(B类)及面上项目、国家重点研发计划青年项目等。现任中国医药生物技术协会疾病模型专业委员及中国研究型医院学会微生物感染与转化专业委员,《中国生物化学与分子生物学报》及Frontiers in Bioengineering and Biotechnology等期刊编委。



2. 研究方向与领域:

课题组致力于开发和运用表观遗传编辑、功能基因组学、生物信息学等方法研究表观遗传调控紊乱在机体发育、肿瘤及其他重大疾病发生发展中的作用。主要包括:

1. 新型表观遗传编辑系统的开发及其在疾病治疗中的应用

2. 肿瘤与微环境的互作及其表观遗传调控机制

3. 病原微生物与宿主互作的表观遗传机制研究


3. 主要代表作:

(#Co-first author; *Co-corresponding author)

  1. Shi L#, Li S#, Zhu R#, Lu C#, Xu X, Li C, Huang X, Zhao X*, Mao F*, Li K*. CRISPRepi: a  multi-omic atlas for CRISPR-based epigenome editing. Nucleic Acids   Research, 2024;, gkae1039, https://doi.org/10.1093/nar/gkae1039

  2. Yang Y#, Wen D#, Lin F#, Song X, Pang R, Sun W, Yu D, Zhang Z, Yu T, Kong J, Zhang L, Cao X, Liao W, Wang D, Yang Q, Liang J, Zhang N, Li K*, Xiong C*, Liu Y*. Suppression of non-muscle myosin II boosts T cell cytotoxicity against tumor. Sci Adv. 2024 Nov;10(44):eadp0631.

  3. Li K*, Wei G*, Yin Y*, Feng J*. Targeting Noncoding Cis-regulatory Elements for Cancer Therapy in Context of 3D Genome. Cancer Discov. 2024 Nov 1;14(11):2061-2065.

  4. Zhang T#, Qiu L#, Cao J#, Li Q#, Zhang L#, An G, Ni J, Jia H,  Li S*, Li K*. ZFP36 loss-mediated BARX1 stabilization promotes malignant phenotypes by transactivating master oncogenes in NSCLC. Cell Death Dis. 2023 Aug 16;14(8):527.

  5. Cao F#, Jiang Y#, Chang L, Du H, Chang D, Pan C, Huang X, Yu D, Zhang M, Fan Y, Bian X*, Li K*. High-throughput functional screen identifies YWHAZ as a key regulator of pancreatic cancer metastasis. Cell Death Dis. 2023 Jul 14;14(7):431.

  6. Chang D, Du H, Chen X, Bian X, Tian W, Shen J, Wei Y, Jiang Y,  Dela Cruz C, Xie L*, Sharma L*, Li K*. A controlled random gene perturbation method identifies ARPC1B gene as a key regulator of cancer metastasis. Genes Dis. 2022 Jul 7;10(3):687-689.

  7. Yao Y#, Ye F#, Li K#, Xu P, Tan W, Feng Q*, Rao S#*. Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19. Signal Transduct Target Ther. 2021 Feb 22;6(1):85.

  8. Li K#, Zhang Y#, Liu X#, Liu Y#, Gu Z, Cao H, Dickerson KE, Chen M, Chen W, Shao Z, Ni M, Xu J*. Noncoding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies. Cancer Discov. 2020 May;10(5):724-745.

  9. Li K#, Liu Y#, Cao H, Zhang Y, Gu Z, Liu X, Yu A, Kaphle P, Dickerson KE, Ni M, Xu J*. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing. Nat Commun. 2020 Jan 24;11(1):485. doi: 10.1038/s41467-020-14362-5.

  10. Huang J#, Li K#, Cai W, Liu X, Zhang Y, Orkin SH, Xu J*, Yuan GC*. Dissecting super-enhancer hierarchy based on chromatin interactions. Nat Commun. 2018 Mar 5;9(1):943.